Search | GSK

ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen

Media

First published: 10 July 2019

Week 48 results from the TANGO study will be presented this month at 10th International AIDS Society Conference on HIV Science (IAS 2019).

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-phase-iii-study-meets-primary-endpoint/

ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection

Media

First published: 24 July 2019

Data from the TANGO study presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) demonstrate non-inferior efficacy of Dovato▼ (dolutegravir/lamivudine) in virally sup...

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-week-48-results-in-first-study-to-evaluate-treatment-switch-from-taf-containing-regimen/

ViiV Healthcare Announces CHMP positive opinion to lower the age and weight limit for Tivicay® (dolutegravir) in children and adolescents living with HIV in Europe

Media

First published: 16 December 2016

The CHMP has adopted a positive opinion to reduce the weight and age limit for the treatment of HIV with Tivicay.

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-chmp-positive-opinion-to-lower-the-age-and-weight-limit-for-tivicay-dolutegravir-in-children-and-adolescents-living-with-hiv-in-europe/

ViiV Healthcare receives EU marketing authorisation for Triumeq® (dolutegravir/abacavir/lamivudine), a new once-daily single-pill regimen for the treatment of HIV

Media

First published: 03 September 2014

ViiV Healthcare announced today that the European Commission (EC) has granted marketing authorisation for Triumeq® (dolutegravir 50mg / abacavir 600mg / lamivudine 300mg) tablets for the treatment ...

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-eu-marketing-authorisation-for-triumeq-dolutegravirabacavirlamivudine-a-new-once-daily-single-pill-regimen-for-the-treatment-of-hiv/

ViiV Healthcare presents data from Phase III study of dolutegravir vs raltegravir in treatment-experienced adults with HIV-1

Media

First published: 06 March 2013

ViiV Healthcare presents 24-week interim results from Phase III SAILING study at the 20th Conference on Retroviruses and Opportunistic Infections (CROI)

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-data-from-phase-iii-study-of-dolutegravir-vs-raltegravir-in-treatment-experienced-adults-with-hiv-1/

Shionogi-ViiV Healthcare announces completion of initial clinical registration package for dolutegravir in HIV

Media

First published: 04 October 2012

Shionogi-ViiV Healthcare LLC today announced that the phase III data required for initial regulatory filings of the investigational integrase inhibitor dolutegravir in adults infected with HIV are ...

https://www.gsk.com/en-gb/media/press-releases/shionogi-viiv-healthcare-announces-completion-of-initial-clinical-registration-package-for-dolutegravir-in-hiv/

GSK and Enigma Diagnostics announce commercial partnership to develop point-of-care influenza diagnostics

Media

First published: 20 July 2009

GlaxoSmithKline (GSK) and Enigma Diagnostics Limited today announced that they have signed worldwide agreements to develop and supply the first point-of-care diagnostic influenza tests to identify ...

https://www.gsk.com/en-gb/media/press-releases/gsk-and-enigma-diagnostics-announce-commercial-partnership-to-develop-point-of-care-influenza-diagnostics/

GSK and Concert Pharmaceuticals form alliance to develop novel deuterium-modified drugs

Media

First published: 01 June 2009

GlaxoSmithKline (NYSE: GSK) and Concert Pharmaceuticals announced today that they will collaborate to develop and commercialise deuterium-containing medicines. The deal includes three of Concert&#8...

https://www.gsk.com/en-gb/media/press-releases/gsk-and-concert-pharmaceuticals-form-alliance-to-develop-novel-deuterium-modified-drugs/

GlaxoSmithKline update: influenza A (H1N1)

Media

First published: 30 April 2009

GlaxoSmithKline (GSK) is committed to supporting governments and health authorities around the world to respond to the emergence of the new influenza A (H1N1) strain.

https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-influenza-a-h1n1/

Phase II study results showed comparable viral suppression rates at 96 weeks for a two-drug regimen of long-acting cabotegravir and rilpivirine and a three-drug regimen in patients with HIV

Media

First published: 24 July 2017

LATTE-2 study results published in The Lancet and presented at International AIDS Society Meeting

https://www.gsk.com/en-gb/media/press-releases/phase-ii-study-results-showed-comparable-viral-suppression-rates-at-96-weeks/